Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05636228 · ClinicalTrials.gov registry record · Phase 2
Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
A Phase 2 study of Acute Infectious Keratoconjunctivitis, sponsored by Invirsa.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 12
- Study locations
NCT05636228: Completed Phase 2 study of Acute Infectious Keratoconjunctivitis, sponsored by Invirsa.
NCT05636228 is a Phase 2 study of Acute Infectious Keratoconjunctivitis that has completed, run by Invirsa. The registered enrollment target is 93 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower). The trial reports 12 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05636228, a Phase 2 study of Acute Infectious Keratoconjunctivitis, has completed, sponsored by Invirsa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 12
- Study locations
Study Summary
Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK). Participants will return for a follow up visit 1 week after end of treatment.
Primary Outcome
To evaluate the efficacy of INV-102 compared to vehicle control in reducing Combined Clinical Score (bulbar hyperemia plus conjunctival discharge) in patients with AIK. Conjunctival hyperemia will be rated by using the modified version of Cornea and Contact Lens Research Unit grading scale for bulbar redness, which ranges from 0 (none) to 4 points (very severe). Conjunctival discharge will be assessed using the chart below from Schwab and Friedlander (2002) to score conjunctival discharge from 0
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG INV-102
Study Locations (12)
Florida
- Shettle Eye Research - Largo
- D & H National Research Centers, INC - Miami
- My Community Research Center, Inc. - Miami
- Quantum Clinical Trials - Miami Beach
California
- Global Research Management - Glendale
- Foothill Eye Institute - Pasadena
Other
- King Chulalongkorn Memorial Hospital - Bangkok
- Mahidol university - Bangkok
Kansas
- Kannarr Eye Center - Pittsburg
North Carolina
- Oculos Clinical Research - Garner
Ohio
- Athens Eye Care - Athens
Texas
- Revolution Research/ Lake Travis Eye and Laser Center - Lakeway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2023-06-09 |
| Est. Completion | 2024-08-22 |
| Phase | Phase 2 |
What the finished NCT05636228 record still lists
NCT05636228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Acute Infectious Keratoconjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT05636228 lists 12 locations in 7 states (Florida, California, Other).
Frequently Asked Questions
What is clinical trial NCT05636228 about?
NCT05636228 is a clinical study titled "Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis". Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK). Participants will return for a follow up visit 1 week after end of treatment.
What is the current status of trial NCT05636228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2023-06-09. Estimated completion is 2024-08-22.
What conditions does trial NCT05636228 study?
This clinical trial studies the following conditions: Acute Infectious Keratoconjunctivitis.
What interventions are being tested in trial NCT05636228?
The interventions under investigation include: Vehicle (DRUG), INV-102 (DRUG).
Who is sponsoring clinical trial NCT05636228?
This trial is sponsored by Invirsa, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05636228 being conducted?
This trial has 12 study locations across California, Florida, Kansas, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05636228's enrollment target sits among peer trials
93 766th of 2000 higher than 1,234 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI